Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
about
Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.Trizivir.Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily.Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection.Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.The role of formulation on the pharmacokinetics of antiretroviral drugs.Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects.A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects.Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.Absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects.
P2860
Q33394593-12DF726F-D1AE-427B-925C-EBE94BD7BDE7Q34628638-A24712B3-EFA2-4BD6-AEAD-37B563AFA4DBQ35005426-36F71C12-0704-42CC-9DE5-F051C32724DEQ35233168-FC3316FC-3C23-451E-9A3A-659BB7456DE0Q36739802-86FFF80D-E309-4615-B855-3821B4A1E326Q38030981-33E49642-E9D8-47F8-A565-A0B6A4793FF5Q38216047-E93B1DED-916D-4070-9751-5407957AAC9BQ38541809-F84EE1B8-CDD0-467A-BA6E-82592B72214EQ38868724-938BAF57-5EB5-417F-8887-4FA72E3615D8Q38872017-257BF6C5-89EA-43C7-BEA5-18CE631A2EF2Q43996453-566F842C-63DC-415B-85C9-D341F762A253Q44657176-B9761151-1E77-4334-BA43-BF5E312B15E0Q46954371-573E320D-F48B-4536-BABE-8BB7D80CCF2C
P2860
Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Abacavir/lamivudine/zidovudine ...... effect of food on absorption.
@en
Abacavir/lamivudine/zidovudine ...... effect of food on absorption.
@nl
type
label
Abacavir/lamivudine/zidovudine ...... effect of food on absorption.
@en
Abacavir/lamivudine/zidovudine ...... effect of food on absorption.
@nl
prefLabel
Abacavir/lamivudine/zidovudine ...... effect of food on absorption.
@en
Abacavir/lamivudine/zidovudine ...... effect of food on absorption.
@nl
P2093
P2860
P1476
Abacavir/lamivudine/zidovudine ...... effect of food on absorption.
@en
P2093
H W Hutman
N F Thompson
T L Allsup
W B Mahony
P2860
P304
P356
10.1177/00912700122010096
P577
2001-03-01T00:00:00Z